Labcorp (LH)
(Delayed Data from NYSE)
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$229.69 USD
-1.01 (-0.44%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $229.74 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
What's in Store for Edwards Lifesciences (EW) Q2 Earnings?
by Zacks Equity Research
Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Improvement in demand at non-COVID business and continued strength in Bio-Rad's (BIO) Life Science segment are likely to have contributed to Q2 results.
LabCorp (LH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued adoption of Invisalign Clear Aligners and iTero scanners are expected to have contributed to the Align Technology's (ALGN) second-quarter 2021 results.
Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.
Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings
by Zacks Equity Research
Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.
Quest Diagnostics (DGX) Expands Testing Access With CLX Pact
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 testing will be available through TrustAssure platform for international travelers and live event attendants.
Cardinal Health (CAH) Introduces 2 New Digital Solutions
by Zacks Equity Research
Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Base Test Rebound to Drive Quest Diagnostics (DGX) Q2 Earnings
by Zacks Equity Research
Quest Diagnostics' (DGX) second-quarter performance within its non-COVID base business might have registered significant sales rebound.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Are Investors Undervaluing LabCorp (LH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LH vs. CNMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LH vs. CNMD: Which Stock Is the Better Value Option?
Lower COVID-19 Testing Demand to Drag Abbott (ABT) Q2 Earnings
by Zacks Equity Research
Apart from COVIG-19 test related hiccups, Abbott (ABT) is likely to have suffered from significant sales decline within its pediatric nutrition business in Q2.
Integra's (IART) SurgiMend Gets Innovative Technology Contract
by Zacks Equity Research
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
Thermo Fisher's (TMO) New Pact Drives Sustainable Lab Practices
by Zacks Equity Research
Thermo Fisher (TMO) expects to ACT label more than 1,200 additional SKUs to allow research, pharmaceutical and clinical laboratories to achieve their sustainability objectives.
Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio
by Zacks Equity Research
Investors are optimistic about Hill-Rom (HRC) on robust international growth and raised 2021 outlook.
Thermo Fisher's (TMO) Rapid DNA Solution Gets FBI Approval
by Zacks Equity Research
Thermo Fisher's (TMO) RapidHIT ID DNA Booking System allows seamless integration of Rapid DNA into the law enforcement booking agency process.
Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by strong diagnostic arm growth and improvement in base business.
What Makes Align Technology (ALGN) a Solid Choice Right Now?
by Zacks Equity Research
Strong performance and latest innovations in the Invisalign and iTero family are driving the top line for Align Technology (ALGN).
LabCorp (LH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
5 Lucrative Picks Based on PEG Ratio for GARP Investors
by Urmimala Biswas
Here are five out of the 10 stocks, ASO, LB, PTR, LH, and HIBB, based on hybrid GARP investment strategy.
LabCorp (LH) Expands Testing Portfolio With the Launch of CDx
by Zacks Equity Research
LabCorp's (LH) new test expands the company's leadership in bringing testing solutions for new precision medicines used to treat patients with lung cancer.
Myriad Genetics (MYGN) Divests Myriad RBM to Focus on Core Units
by Zacks Equity Research
Myriad Genetics' (MYGN) new divesture will enable company to accelerate the execution of transformation plan and drive growth.